- Home
- TCRX vs JAGU Comparison
TCRX vs JAGU Comparison
Compare TCRX & JAGU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
Current Price
$1.18
Company Overview
Basic Information| Metric | TCRX | JAGU |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 63.6M | 63.2M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | TCRX | JAGU |
|---|---|---|
| Price | $1.18 | $1.80 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 8 | 0 |
| Target Price | ★ $8.00 | N/A |
| AVG Volume (30 Days) | ★ 465.2K | 424.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 12.28 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $10,325,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $69.75 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 266.65 | N/A |
| 52 Week Low | $0.88 | $2.25 |
| 52 Week High | $2.57 | $3.60 |
Technical Indicators
Market Signals| Indicator | TCRX | JAGU |
|---|---|---|
| Relative Strength Index (RSI) | 61.50 | 29.58 |
| Support Level | $1.16 | N/A |
| Resistance Level | $1.23 | $3.49 |
| Average True Range (ATR) | 0.08 | 0.46 |
| MACD | 0.02 | -0.09 |
| Stochastic Oscillator | 71.80 | 0.14 |
Price Performance
Historical Comparison TCRX
JAGU
About TCRX TScan Therapeutics Inc.
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.